Durvalumab Plus Chemo Receives FDA Approval in Locally Advanced/Metastatic Biliary Tract Cancer


Patients with locally advanced or metastatic biliary tract cancer can now receive treatment with durvalumab plus gemcitabine following the combination’s approval by the FDA.

The FDA has granted approval to a combination of durvalumab (Imfinzi) and gemcitabine in adult patients with locally advanced or metastatic biliary tract cancer, according to a press release from the FDA.

The combination was evaluated as part of the phase 3 TOPAZ-1 trial (NCT03875235), which included a total of 685 patients with histologically confirmed locally advanced unresectable or metastatic disease who have not previously received treatment with systemic therapy for advanced biliary tract cancer. The median overall survival in the durvalumab arm was 12.8 months (95% CI, 11.1-14.0) compared with 11.5 months (95% CI, 10.1-12.5) in the placebo arm (HR, 0.80; 95% CI, 0.66-0.97; P = .021). Moreover, the median progression-free survival was 7.2 months (95% CI, 6.7-7.4) and 5.7 months (95% CI, 5.6-6.7) in each respective arm. Additionally, the investigator-assessed overall response rate was 27% (95% CI, 22%-32%) in the durvalumab arm and 19% (95% CI, 15%-23%) in the placebo arm.

Durvalumab has a recommended dose of 1500 mg every 3 weeks for those with a weight of more than 30 kg when administered with gemcitabine and cisplatin with a 1500-mg subsequent dose every 4 weeks as a monotherapy until disease progression or unacceptable toxicity. Those who weigh less than 30 kg have a recommended dose of 20 mg/kg every 3 weeks with gemcitabine and cisplatin with a subsequent dose of 20 mg/lg every 4 weeks until progression or unacceptable toxicity.

Common adverse effects included fatigue, nausea, constipation, decreased appetite, abdominal pain, rash, and pyrexia.


FDA approves durvalumab for locally advanced or metastatic biliary tract cancer. News release. FDA. September 2, 2022. Accessed September 2, 2022. https://bit.ly/3edCUWt

Related Videos
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content